GlassScriptPhysician profile
Ashok K Komarla
NPI 1790882439
$1,406.84
in general payments reported to CMS, 2019-2025
13 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.91 · 2020: $23.81 · 2021: $18.34 · 2023: $364 · 2024: $679 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.80 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $345.46 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $191.81 | 2019-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $172.21 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.14 | 2023-2024 | Caplyta |
| Abbvie INC. | $120.29 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $111.56 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $83.80 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $81.74 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $51.79 | 2024 | Fanapt, Hetlioz |
| Indivior INC. | $44.94 | 2023-2024 | Perseris |
| Medtronic, INC. | $24.81 | 2023 | Intellis Adaptivestim |
| Sunovion Pharmaceuticals INC. | $23.81 | 2020 | |
| Neuronetics, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Komarla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.